Dr. Manish Tandon, who has full experience in business development in the biopharmaceutical sector, was today announced as Vice President of Business Development, reporting to Dr. Cui Yusong, Co-Founder, Chairman and CEO of Noshon Jianhua, responsible for the company's business development strategy and execution, external cooperation, licensing and external licensing, and commercial mergers and acquisitions.
Tandon has over 20 years of experience in business development, mergers and acquisitions and new drug development in the biopharmaceutical industry.
joining Novarthren, Dr. Tandon served as Vice President of ArQule, an oncology drug research and development company, responsible for business development, strategic partnerships, new product development and IP management.
Tandon has comprehensive trading experience in the biopharmaceutical industry.
Tandon played a key role in Mercedon's $2.7 billion acquisition of ArQule.
, he also successfully signed two exclusive licensing agreements with Barcelona Pharmaceuticals and Shanghai Lunsheng Pharmaceuticals for Dracini.
Tandon holds a Ph.D. in Chemistry from Brown University and completed postdoctoral research at Cornell University, where he also received an MBA from Boston University's Kestrom School of Business.
Tandon received his bachelor's degree in chemistry from the University of Delhi, India.
note: There are deletions in the original text.